Background: Asprosin is a fasting-induced adipokine involved in glucose homeostasis and inflammation; its relationship with periodontal and oral diseases is uncertain. Methods: Following the Joanna Briggs Institute (JBI) guidance and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR), four databases were searched and supplemented by citation searching. Human and animal evidence was mapped separately and appraised with JBI checklists and the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. Results: Thirteen reports were included: 11 human studies (1176 reported participants) and 2 rat studies. Eight human studies reported higher asprosin in periodontal or peri-implant inflammation than in health, whereas two with tighter metabolic restriction did not. Healthy-control concentrations from enzyme-linked immunosorbent assays (ELISAs) of seven sources differed by over three orders of magnitude, and five studies reported values outside the stated assay range or sensitivity. Areas under the receiver operating characteristic curve (AUCs) for periodontitis versus health ranged from 0.60 to 1.00, but asprosin also separated groups defined by diabetes, polycystic ovary syndrome or central adiposity, and all periodontal diagnostic analyses were at high risk of bias. Conclusions: The small, heterogeneous, predominantly cross-sectional evidence does not separate periodontal from metabolic influences; asprosin may reflect a combined periodontal–metabolic inflammatory burden rather than a periodontal-specific signal. Assay harmonisation and metabolically controlled longitudinal studies are needed before diagnostic use.